
|Videos|April 8, 2022
Improving the Care Continuum
An expert advises how to optimize the care continuum for patients with ASCVD.
Advertisement
Episodes in this series

Advertisement
Related to this article

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.

Independent VESALIUS-CV analysis finds evolocumab cost-effective at about 36% below the ACC/AHA benchmark for patients without prior MI or stroke.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
3
FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis
4
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MD
5



